$SCL

Stepan Reports Third Quarter 2026 Results

STEPAN CO (SCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stepan Reports Third Quarter 2026 Results Northbrook, Illinois, October 28, 2026 -- Stepan Company (NYSE: SCL) today reported: Third Quarter 2026 Highlights • Reported net income was $17.8 million, up 64% versus the prior year. Adjusted net income (1) was $21.7 milli

Original reporting
Published Oct 28, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SCL
Bullish
high confidence
Mentioned
$SCL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SCLBullishHigh
01

Why it matters

The earnings release provides fresh data on revenue, profitability, and cash flow, which were all up year‑over‑year.

02

Market read

First‑report earnings data for a mid‑cap chemicals firm; likely to move the stock and influence sector sentiment.

03

What to watch

Restructuring charge of $5.6 M and higher working capital needs could temper cash flow benefits.

Relevance 7/10Novelty 8/10Timing: today

Background

Stepan Company (NYSE:SCL) filed a Form 8‑K reporting its third‑quarter 2026 financial results.

Company-level read

Ticker impact

$SCLBullishHigh confidence
Context

Stepan reported Q3 2026 results with net income up 64% YoY and adjusted EBITDA up 18% YoY.

Expected impact

upward pressure as market prices in strong earnings growth

Evidence & confidence

Robust profit and EBITDA growth, plus cash from operations, suggest improved fundamentals and may lift the stock.

Market effects

Positive for the specialty chemicals and surfactants sector as Stepan shows strong volume and margin recovery.

U.S. chemicals market may see modest rally on earnings beat.

Highlights resilience in industrial chemicals amid global supply chain disruptions.

Counterpoint

If the market had already priced in strong results, the beat may be muted and the stock could face profit‑taking.

Key entities

  • Stepan Company

    U.S. specialty chemicals producer.

  • Luis E. Rojo

    President and CEO of Stepan, quoted on results.

Related articles

$SCLMed

Stepan Q3 Earnings Call Highlights

Stepan Company (NYSE: SCL) reported Q3 net sales up 12% to $27M, with adjusted EBITDA rising 5% to $11.7M. Management cited higher volume in MCT products and cost pressures from volatile oil markets. Project Catalyst savings exceeded expectations, with $23M quarterly savings and $66M-$70M expected for 2026. Net debt reduced to $536M, and the dividend was raised by 2.5%.

$SCLMedAI 8/10

Stepan Q3 2026 slides: EPS doubles on volume growth, restructuring

Stepan Company (SCL) reported Q3 2026 adjusted EPS of $0.94, up 98% YoY, driven by 7% volume growth and restructuring savings. Revenue and EPS beat estimates. Shares rose 2.42%. Adjusted EBITDA increased 18% to $66.3M. Project Catalyst restructuring is ahead of schedule, with $23M quarterly savings. Net leverage ratio improved to 2.4x. Free cash flow was $8M, impacted by working capital build.

$SCLMed

Stepan Company Q2 2026 Earnings Call Summary

Strategic Performance Drivers Adjusted EBITDA growth of 45% was driven by a combination of 6% organic volume growth, disciplined pricing execution, and ramping productivity gains. Surfactant performance benefited from broad-based demand across all end markets, specifically led by industrial cleaning, laundry, and oil field sectors. Margin recovery was achieved through the rigorous application of contractual pass-through mechanisms and pricing actions to offset fluctuating raw material costs.

$SCLMedAI 8/10

Stepan Reports Second Quarter 2026 Results

Stepan (NYSE: SCL) reported Q2 2026 net income of $22.9M, up 102% year over year, and adjusted net income of $27.1M, up 126%. Adjusted EBITDA rose 45% to $74.4M. Net sales increased 15% to $684.1M, with organic volume up 6%. Free cash flow was -$15.0M due to working capital. The company plans to cut about 100 salaried roles under Project Catalyst and expects full-year restructuring charges of $75.0M-$80.0M.